Storyline
Pfizer’s atirmociclib shows positive phase 2 results in second-line metastatic breast cancer
Pfizer announced positive phase 2 results for atirmociclib, a CDK4-selective inhibitor, in second-line ER+ metastatic breast cancer.
Evidence locked
Today's free sample is only available for the edition's flagship storyline.
Evidence preview
- Fierce Biotechfiercebiotech.com
- Pfizer’s Ibrance successor moves forward with new study dataBioPharma Dive
- Pfizer Delivers Phase 2 Win in 2nd Line ER+ Metastatic Breast Cancer with CDK4-Selective Inhibitor, Atirmociclib + Fu...biotech